首页 > 最新文献

Clinical and Experimental Allergy最新文献

英文 中文
Efficacy and Safety of Subcutaneous vs. Sublingual Immunotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis. 过敏性鼻炎皮下注射与舌下含服免疫疗法的疗效与安全性:系统回顾与元分析》。
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-29 DOI: 10.1111/cea.14574
Shambo Samrat Samajdar, Saibal Moitra, Sougata Sarkar, Santanu K Tripathi
{"title":"Efficacy and Safety of Subcutaneous vs. Sublingual Immunotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis.","authors":"Shambo Samrat Samajdar, Saibal Moitra, Sougata Sarkar, Santanu K Tripathi","doi":"10.1111/cea.14574","DOIUrl":"https://doi.org/10.1111/cea.14574","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time Trends, Regional Variation and Associations of Low-Allergy Formula Prescribing in England 英格兰低过敏配方奶粉处方的时间趋势、地区差异和关联。
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-27 DOI: 10.1111/cea.14570
Karen H. T. Li, Olivia Wing, Hilary I. Allen, Timothy D. H. Smith, Frank Moriarty, Robert J. Boyle

Background

Cow's milk allergy (CMA) overdiagnosis appears to be increasing and is associated with excessive low-allergy formula prescription. We evaluated recent trends and regional variation in low-allergy formula prescribing for CMA in England, and assessed potential risk factors for higher prescribing rates.

Methods

Data on national and regional prescribing of low-allergy formulas were extracted from England's electronic prescription database using R. Region-level factors were evaluated for potential associations with regional low-allergy formula prescription rates using multivariate linear regression. Analysis of national prescribing trends covered 2007–2023, analysis of regional variation and region-level factors examined 2017–2019, prior to a re-organisation of the regional healthcare structure in England.

Results

Low-allergy formula prescribing increased from 6.1 to 23.3 L per birth nationally, between 2007 and 2023. Regional prescribing rate varied from 0.8 to 47.6 L per birth in 2017–2019. We found significant associations between regional low-allergy formula prescribing rate and regional prescribing rates for milk feed thickeners Gaviscon Infant and Carobel Instant (β = 0.10, p < 0.01), and for other anti-reflux medications used in young children (β = 0.89 p < 0.01). Inconsistent associations were seen with prescribing junior adrenaline auto-injectors and oral antibiotics. A model including these four variables accounted for 37% of regional variation in low-allergy formula prescribing rate. Region-level socio-economic deprivation, CMA guideline recommendations and paediatric allergy service provision were not associated with low-allergy formula prescribing.

Conclusions

Low-allergy formula prescribing in England is increasing, varies significantly by region and is consistently associated with prescribing rates for milk feed thickeners and other anti-reflux medication for young children. Community prescribing behaviours may be important determinants of CMA overdiagnosis.

背景:牛奶过敏(CMA)的过度诊断率似乎正在上升,这与过多的低敏配方奶粉处方有关。我们评估了英格兰针对 CMA 的低敏配方奶粉处方的最新趋势和地区差异,并评估了处方率较高的潜在风险因素:使用多变量线性回归法评估了地区级因素与地区低过敏配方奶粉处方率的潜在关联。对2007-2023年全国处方趋势进行了分析,对2017-2019年(英格兰地区医疗结构重组之前)的地区差异和地区级因素进行了分析:2007年至2023年间,全国低过敏配方奶粉处方量从每胎6.1升增至23.3升。2017-2019 年,地区处方率从每名新生儿 0.8 升到 47.6 升不等。我们发现,地区低过敏配方奶粉处方率与奶粉增稠剂佳维乐婴儿配方奶粉和卡乐宝速溶配方奶粉的地区处方率之间存在明显关联(β = 0.10,p 结论:地区低过敏配方奶粉处方率与奶粉增稠剂佳维乐婴儿配方奶粉和卡乐宝速溶配方奶粉的地区处方率之间存在明显关联:英格兰的低过敏配方奶粉处方量在不断增加,各地区的差异很大,而且与幼儿奶粉增稠剂和其他抗反流药物的处方率始终相关。社区处方行为可能是 CMA 过度诊断的重要决定因素。
{"title":"Time Trends, Regional Variation and Associations of Low-Allergy Formula Prescribing in England","authors":"Karen H. T. Li,&nbsp;Olivia Wing,&nbsp;Hilary I. Allen,&nbsp;Timothy D. H. Smith,&nbsp;Frank Moriarty,&nbsp;Robert J. Boyle","doi":"10.1111/cea.14570","DOIUrl":"10.1111/cea.14570","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cow's milk allergy (CMA) overdiagnosis appears to be increasing and is associated with excessive low-allergy formula prescription. We evaluated recent trends and regional variation in low-allergy formula prescribing for CMA in England, and assessed potential risk factors for higher prescribing rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data on national and regional prescribing of low-allergy formulas were extracted from England's electronic prescription database using R. Region-level factors were evaluated for potential associations with regional low-allergy formula prescription rates using multivariate linear regression. Analysis of national prescribing trends covered 2007–2023, analysis of regional variation and region-level factors examined 2017–2019, prior to a re-organisation of the regional healthcare structure in England.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Low-allergy formula prescribing increased from 6.1 to 23.3 L per birth nationally, between 2007 and 2023. Regional prescribing rate varied from 0.8 to 47.6 L per birth in 2017–2019. We found significant associations between regional low-allergy formula prescribing rate and regional prescribing rates for milk feed thickeners Gaviscon Infant and Carobel Instant (<i>β</i> = 0.10, <i>p</i> &lt; 0.01), and for other anti-reflux medications used in young children (<i>β</i> = 0.89 <i>p</i> &lt; 0.01). Inconsistent associations were seen with prescribing junior adrenaline auto-injectors and oral antibiotics. A model including these four variables accounted for 37% of regional variation in low-allergy formula prescribing rate. Region-level socio-economic deprivation, CMA guideline recommendations and paediatric allergy service provision were not associated with low-allergy formula prescribing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Low-allergy formula prescribing in England is increasing, varies significantly by region and is consistently associated with prescribing rates for milk feed thickeners and other anti-reflux medication for young children. Community prescribing behaviours may be important determinants of CMA overdiagnosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"909-918"},"PeriodicalIF":6.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14570","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dupilumab Improves Clinical Symptoms and Biomarkers in Comorbid Seasonal Timothy Grass Pollen Allergic Rhinitis in Patients With CRSwNP. 杜匹单抗可改善CRSwNP患者合并季节性提摩西草花粉过敏性鼻炎的临床症状和生物标志物
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-26 DOI: 10.1111/cea.14572
Caroline Beutner, Stephan Traidl, Martin Wagenmann, Moritz Maximilian Hollstein, Dirk Beutner, Michael Peter Schön, Timo Buhl
{"title":"Dupilumab Improves Clinical Symptoms and Biomarkers in Comorbid Seasonal Timothy Grass Pollen Allergic Rhinitis in Patients With CRSwNP.","authors":"Caroline Beutner, Stephan Traidl, Martin Wagenmann, Moritz Maximilian Hollstein, Dirk Beutner, Michael Peter Schön, Timo Buhl","doi":"10.1111/cea.14572","DOIUrl":"https://doi.org/10.1111/cea.14572","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Validation of a Prognostic Clinical Risk Score for Subsequent Atopic Dermatitis Risk. 开发并验证特应性皮炎后续风险的临床预后风险评分。
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-24 DOI: 10.1111/cea.14567
Tamar Landau, Keren Gamrasni, Alex Levin, Yotam Barlev, Oliver Sanders, Shira Benor, Michael Brandwein
{"title":"Development and Validation of a Prognostic Clinical Risk Score for Subsequent Atopic Dermatitis Risk.","authors":"Tamar Landau, Keren Gamrasni, Alex Levin, Yotam Barlev, Oliver Sanders, Shira Benor, Michael Brandwein","doi":"10.1111/cea.14567","DOIUrl":"https://doi.org/10.1111/cea.14567","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating Patients Into Programmes to Address the Allergy Knowledge Practice Gap 将患者纳入计划,消除过敏知识实践差距。
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-24 DOI: 10.1111/cea.14563
John O. Warner, Sophie Jacoba Irma Maria Spitters

There is a wide gap between the first publication of new treatments with efficacy and their successful application in clinical practice. In many respects, the management of allergic diseases is a good exemplar of the knowledge/practice gap. It was assumed that systematic reviews and publication of guidelines would ensure timely delivery of effective care, but this has not proved to be the case. While there are many reasons to explain shortcomings in healthcare delivery, the lack of patient and carer involvement in the planning of research, evidence review, guideline development and guideline implementation is most compelling. To achieve adherence to evidence-based guidelines consistently across all levels of the health service requires the implementation of integrated care with clear pathways through which patients can navigate. Quality improvement methodology could be employed to plan and implement integrated care pathways (ICPs). There is evidence that ICPs achieve improved outcomes for acute hospital-based interventions, but less work has focussed on long-term conditions where more diverse agencies are involved. At all stages, stakeholder representation from the full range of healthcare professionals, patients, their families, social services, education, local government and employers must be involved. In this article we review the step-wise and iterative process by which knowledge is implemented into practice to improve patient experience and outcomes We argue how this process can benefit from the involvement of patients and their carers as equal partners, and we discuss how different initiatives have involved patients with allergic diseases. There currently is a gap in evidence that links patient involvement to improved outcomes. We recommend the use of the Core Outcome Sets (COS) and Patient Reported Experience Measures (PREMS) which have been developed for allergic diseases to monitor the effects of implementation research and the impact of patient and carer involvement on outcomes.

从首次公布具有疗效的新疗法到将其成功应用于临床实践之间存在着巨大的差距。在许多方面,过敏性疾病的治疗就是知识/实践差距的典范。人们原以为系统性综述和指南的出版能确保及时提供有效的治疗,但事实证明并非如此。虽然有很多原因可以解释医疗保健服务中存在的不足,但患者和护理人员在研究规划、证据审查、指南制定和指南实施中缺乏参与是最令人信服的。要想在各级医疗服务中始终如一地遵守循证指南,就必须实施综合护理,为患者提供清晰的路径。质量改进方法可用于规划和实施综合护理路径(ICPs)。有证据表明,综合护理路径改善了以急症医院为基础的干预措施的效果,但对于涉及更多不同机构的长期病症,这方面的工作较少。在各个阶段,都必须有来自医疗保健专业人员、患者、患者家属、社会服务、教育、地方政府和雇主等各方面的利益相关者参与。在这篇文章中,我们回顾了将知识转化为实践以改善患者体验和治疗效果的循序渐进的迭代过程。我们论证了患者及其照护者作为平等伙伴的参与如何使这一过程受益,并讨论了不同的倡议如何让过敏性疾病患者参与其中。目前,将患者参与与改善疗效联系起来的证据还很缺乏。我们建议使用针对过敏性疾病开发的核心结果集 (COS) 和患者报告体验测量 (PREMS),以监测实施研究的效果以及患者和照护者参与对结果的影响。
{"title":"Integrating Patients Into Programmes to Address the Allergy Knowledge Practice Gap","authors":"John O. Warner,&nbsp;Sophie Jacoba Irma Maria Spitters","doi":"10.1111/cea.14563","DOIUrl":"10.1111/cea.14563","url":null,"abstract":"<p>There is a wide gap between the first publication of new treatments with efficacy and their successful application in clinical practice. In many respects, the management of allergic diseases is a good exemplar of the knowledge/practice gap. It was assumed that systematic reviews and publication of guidelines would ensure timely delivery of effective care, but this has not proved to be the case. While there are many reasons to explain shortcomings in healthcare delivery, the lack of patient and carer involvement in the planning of research, evidence review, guideline development and guideline implementation is most compelling. To achieve adherence to evidence-based guidelines consistently across all levels of the health service requires the implementation of integrated care with clear pathways through which patients can navigate. Quality improvement methodology could be employed to plan and implement integrated care pathways (ICPs). There is evidence that ICPs achieve improved outcomes for acute hospital-based interventions, but less work has focussed on long-term conditions where more diverse agencies are involved. At all stages, stakeholder representation from the full range of healthcare professionals, patients, their families, social services, education, local government and employers must be involved. In this article we review the step-wise and iterative process by which knowledge is implemented into practice to improve patient experience and outcomes We argue how this process can benefit from the involvement of patients and their carers as equal partners, and we discuss how different initiatives have involved patients with allergic diseases. There currently is a gap in evidence that links patient involvement to improved outcomes. We recommend the use of the Core Outcome Sets (COS) and Patient Reported Experience Measures (PREMS) which have been developed for allergic diseases to monitor the effects of implementation research and the impact of patient and carer involvement on outcomes.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 10","pages":"723-733"},"PeriodicalIF":6.3,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14563","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional Considerations of Plant-Based Diets for People With Food Allergy 食物过敏者的植物性膳食营养考虑。
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-24 DOI: 10.1111/cea.14557
Jennifer L. P. Protudjer, Franziska Roth-Walter, Rosan Meyer

Plant-based diets (PBD) have been reported throughout history, but are increasingly common in current times, likely in part due to considerable emphasis on climate change and human health and wellness. Many dietary organisations around the world endorse well-planned, nutritionally adequate PBD, which exclude some or all forms of animal-based foods. However, special attention must be given to patients who follow PBD and also have food allergy (FA), as avoidance may increase the risk of developing nutritional deficiencies, including poor growth in children, weight loss in adults and vitamin and mineral deficiencies. Given the increasing prevalence of both PBD and food allergen avoidance diets, healthcare providers are likely to counsel patients with FA who also follow a PBD. In this review, an overview of PBD in patients with FA is provided, including recent trends, macro- and micronutrient needs, and growth for children and weight gain considerations for adults. With regard to a PBD, special attention should be given to ensure adequate fat and protein intake and improving the bioavailability of several minerals such as iron, zinc, iodine, calcium and magnesium, and vitamins such as A, B2, B12 and D. Although the collective data on growth amongst children following a PBD are varied in outcome and may be influenced in part by the type of PBD, growth must be regularly monitored and in adults weight gain assessed as part of any clinical assessment in those people with FA.

植物性膳食(PBD)在历史上就有报道,但在当代越来越普遍,部分原因可能是人们对气候变化和人类健康与福祉的高度重视。世界各地的许多饮食组织都认可计划周密、营养充足的植物性饮食,其中排除了部分或所有形式的动物性食物。但是,必须特别注意那些遵循 PBD 并同时患有食物过敏症(FA)的患者,因为避免进食可能会增加患营养缺乏症的风险,包括儿童发育不良、成人体重减轻以及维生素和矿物质缺乏症。鉴于 PBD 和食物过敏原回避饮食越来越普遍,医疗保健提供者很可能会为同时遵循 PBD 的 FA 患者提供咨询。本综述概述了 FA 患者的 PBD,包括最新趋势、宏量和微量营养素需求、儿童生长和成人体重增加的注意事项。尽管有关儿童生长情况的综合数据结果各异,且可能部分受到 PBD 类型的影响,但必须定期监测生长情况,并在对 FA 患者进行任何临床评估时,评估成人的体重增加情况。
{"title":"Nutritional Considerations of Plant-Based Diets for People With Food Allergy","authors":"Jennifer L. P. Protudjer,&nbsp;Franziska Roth-Walter,&nbsp;Rosan Meyer","doi":"10.1111/cea.14557","DOIUrl":"10.1111/cea.14557","url":null,"abstract":"<p>Plant-based diets (PBD) have been reported throughout history, but are increasingly common in current times, likely in part due to considerable emphasis on climate change and human health and wellness. Many dietary organisations around the world endorse well-planned, nutritionally adequate PBD, which exclude some or all forms of animal-based foods. However, special attention must be given to patients who follow PBD and also have food allergy (FA), as avoidance may increase the risk of developing nutritional deficiencies, including poor growth in children, weight loss in adults and vitamin and mineral deficiencies. Given the increasing prevalence of both PBD and food allergen avoidance diets, healthcare providers are likely to counsel patients with FA who also follow a PBD. In this review, an overview of PBD in patients with FA is provided, including recent trends, macro- and micronutrient needs, and growth for children and weight gain considerations for adults. With regard to a PBD, special attention should be given to ensure adequate fat and protein intake and improving the bioavailability of several minerals such as iron, zinc, iodine, calcium and magnesium, and vitamins such as A, B2, B12 and D. Although the collective data on growth amongst children following a PBD are varied in outcome and may be influenced in part by the type of PBD, growth must be regularly monitored and in adults weight gain assessed as part of any clinical assessment in those people with FA.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"895-908"},"PeriodicalIF":6.3,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14557","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parents' Perspectives on Prevention and Risk Prediction of Food Allergies in Children: A Qualitative Study 家长对儿童食物过敏预防和风险预测的看法:定性研究。
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-22 DOI: 10.1111/cea.14569
Katharina Gerhardinger, Susanne Brandstetter, Madlen Hörold, Magdalena Rohr, Mara König, Christian Apfelbacher
<p>About 6%–8% of children in Western countries develop food allergy (FA) [<span>1</span>], leading to severe, sometimes life-threatening symptoms. Therefore, predicting the risk of and preventing childhood FA is a significant public health concern. The last decades have seen a paradigm shift in allergy prevention [<span>2</span>]. As a result, parents are faced with a wide range of sometimes conflicting information and may encounter additional challenges in finding accurate information, especially online [<span>3</span>]. There is limited qualitative research on childhood FA prevention, as previous studies have focused on the challenges of managing FA [<span>4</span>].</p><p>As part of the NAMIBIO app consortium [<span>5</span>], our qualitative study aimed to systematically describe parental information needs and their information seeking behaviour regarding childhood FA risk prediction and prevention. Additionally, we sought to understand parents´ attitudes towards a health app for early risk prediction and prevention of FA in children [<span>6</span>].</p><p>In 2022, KG, MH, MR and CD conducted 30 semi-structured interviews (each 30–60 min), with parents of children up to 3 years of age in Germany. There was no personal relationship between interviewer and interviewees. Interviewees were parents of children diagnosed with FA (<i>n</i> = 18), at risk of FA (<i>n</i> = 13), or without known risk factors (<i>n</i> = 3) [<span>7</span>]. Using computer-assisted qualitative content analysis [<span>8</span>], we identified five main (deductive) categories and 15 inductive subcategories [<span>7</span>]. Transparency and intersubjectivity were ensured through communicative validation in weekly interpretation work sessions. Through reflection and discussion (prior to conducting our study), we were aware of our assumptions about recruitment, participants, target audience and the value of the planned app and were able to integrate these into the reflective interpretive work.</p><p>Data analysis (Figure 1) revealed varying parental information needs and degrees of healthcare utilisation regarding FA risk prediction and prevention. Parents' information-seeking behaviour was influenced by different reasons. For one, intuition (‘gut feeling’) strongly motivated parents to address FA issues and seek appropriate healthcare or preventive measures (<i>‘[…] it may sound stupid, but intuitively I googled milk protein allergy at the time […]</i>', P27, female, early 30s). For another, pre-existing risk awareness (<i>‘Because I have many allergies […]’</i>, P14, female, late 30s) and occurring symptoms in the child (<i>‘I saw a rash […] and googled it […]’</i>, P06, female, early 40s) influenced the parents' behaviour. Limited competence in finding valuable information was found to be a barrier to prevention and risk prediction of childhood FA (<i>‘[…] the Internet is big and wide’</i>, P15, female, mid 30s). Parents' information needs ranged from no interest (<i>
在西方国家,约有 6%-8% 的儿童会患上食物过敏症(FA)[1],导致严重的症状,有时甚至危及生命。因此,预测和预防儿童食物过敏的风险是一个重要的公共卫生问题。过去几十年来,过敏预防的模式发生了转变[2]。因此,家长们面临着各种有时相互矛盾的信息,在寻找准确信息(尤其是网上信息)时可能会遇到更多挑战[3]。作为 NAMIBIO 应用程序联盟[5]的一部分,我们的定性研究旨在系统地描述家长在儿童过敏症风险预测和预防方面的信息需求及其信息搜索行为。2022 年,KG、MH、MR 和 CD 对德国 3 岁以下儿童的家长进行了 30 次半结构化访谈(每次 30-60 分钟)。访谈者与受访者之间没有私人关系。受访者是已确诊为 FA(18 人)、有 FA 风险(13 人)或无已知风险因素(3 人)的儿童的父母[7]。通过计算机辅助定性内容分析[8],我们确定了五个主要(演绎)类别和 15 个归纳子类别[7]。通过每周口译工作会议上的交流验证,确保了透明度和主体间性。通过反思和讨论(在开展研究之前),我们意识到我们对招募、参与者、目标受众和计划应用程序价值的假设,并能够将这些假设融入反思性解释工作中。数据分析(图 1)显示了家长在 FA 风险预测和预防方面不同的信息需求和医疗保健利用程度。家长寻求信息的行为受到不同原因的影响。其一,直觉("直觉")强烈地促使家长解决 FA 问题并寻求适当的医疗保健或预防措施('[......]这听起来可能很愚蠢,但我当时凭直觉上网搜索了牛奶蛋白过敏[......]',P27,女性,30 岁出头)。另外,已有的风险意识("因为我有很多过敏症[......]",P14,女性,30 岁出头)和孩子出现的症状("我看到皮疹[......]就上网查了一下[......]",P06,女性,40 岁出头)也影响了家长的行为。发现寻找有价值信息的能力有限是预防和预测儿童 FA 风险的一个障碍('[......]互联网又大又广',P15,女性,30 多岁)。家长对信息的需求从没有兴趣('三秒钟都没想过',P15,女性,30 多岁)到明确希望'找出[......]你能做什么来预防'(P22,女性,30 多岁)不等。儿科医生被认为是整个童年期的 "第一接触点"(P22,女性,30 多岁),尽管他们并不总是被视为最相关或最有帮助的预防信息来源。助产士被认为是母乳喂养或辅食喂养等信息的重要来源("助产士的咨询肯定比儿科医生的咨询更深入、更广泛",P26,女性,30 岁出头)。社交媒体,尤其是 Instagram,在父母的信息来源中扮演了重要角色("Instagram,我关注它以获取更多信息",P18,女性,30 岁出头)。大多数家长对预测风险和预防儿童 FA 的应用程序持开放态度,"[......]因为你总是随身带着手机"(P22,女性,30 多岁);他们对输入数据只表示了极少的担忧。他们强调,该应用程序必须科学合理,并由专家开发。我们的研究结果与文献一致,文献显示,FA 通常是家长们不太关心的问题[9]。导致 FA 预防相关性低的几个因素是:(1)家长对 FA 和风险因素的了解和兴趣有限。(2) 许多家长不区分不耐受和过敏,往往认为 FA 不会对以后的生活造成重大负担。(3) 即使家长意识到儿童 FA 的预防,他们也往往缺乏找到 "好的 "健康信息的能力。虽然儿科医生通常是 FA 信息的主要来源,但参与者也依赖多种来源,包括助产士和社交媒体。尽管多种信息来源具有优势,但仍有可能传播相互矛盾或不正确的信息,尤其是在社交媒体上。因此,儿童 FA 预防和风险预测应用程序具有潜力,但必须符合重要标准,才能对家长有所帮助。
{"title":"Parents' Perspectives on Prevention and Risk Prediction of Food Allergies in Children: A Qualitative Study","authors":"Katharina Gerhardinger,&nbsp;Susanne Brandstetter,&nbsp;Madlen Hörold,&nbsp;Magdalena Rohr,&nbsp;Mara König,&nbsp;Christian Apfelbacher","doi":"10.1111/cea.14569","DOIUrl":"10.1111/cea.14569","url":null,"abstract":"&lt;p&gt;About 6%–8% of children in Western countries develop food allergy (FA) [&lt;span&gt;1&lt;/span&gt;], leading to severe, sometimes life-threatening symptoms. Therefore, predicting the risk of and preventing childhood FA is a significant public health concern. The last decades have seen a paradigm shift in allergy prevention [&lt;span&gt;2&lt;/span&gt;]. As a result, parents are faced with a wide range of sometimes conflicting information and may encounter additional challenges in finding accurate information, especially online [&lt;span&gt;3&lt;/span&gt;]. There is limited qualitative research on childhood FA prevention, as previous studies have focused on the challenges of managing FA [&lt;span&gt;4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;As part of the NAMIBIO app consortium [&lt;span&gt;5&lt;/span&gt;], our qualitative study aimed to systematically describe parental information needs and their information seeking behaviour regarding childhood FA risk prediction and prevention. Additionally, we sought to understand parents´ attitudes towards a health app for early risk prediction and prevention of FA in children [&lt;span&gt;6&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;In 2022, KG, MH, MR and CD conducted 30 semi-structured interviews (each 30–60 min), with parents of children up to 3 years of age in Germany. There was no personal relationship between interviewer and interviewees. Interviewees were parents of children diagnosed with FA (&lt;i&gt;n&lt;/i&gt; = 18), at risk of FA (&lt;i&gt;n&lt;/i&gt; = 13), or without known risk factors (&lt;i&gt;n&lt;/i&gt; = 3) [&lt;span&gt;7&lt;/span&gt;]. Using computer-assisted qualitative content analysis [&lt;span&gt;8&lt;/span&gt;], we identified five main (deductive) categories and 15 inductive subcategories [&lt;span&gt;7&lt;/span&gt;]. Transparency and intersubjectivity were ensured through communicative validation in weekly interpretation work sessions. Through reflection and discussion (prior to conducting our study), we were aware of our assumptions about recruitment, participants, target audience and the value of the planned app and were able to integrate these into the reflective interpretive work.&lt;/p&gt;&lt;p&gt;Data analysis (Figure 1) revealed varying parental information needs and degrees of healthcare utilisation regarding FA risk prediction and prevention. Parents' information-seeking behaviour was influenced by different reasons. For one, intuition (‘gut feeling’) strongly motivated parents to address FA issues and seek appropriate healthcare or preventive measures (&lt;i&gt;‘[…] it may sound stupid, but intuitively I googled milk protein allergy at the time […]&lt;/i&gt;', P27, female, early 30s). For another, pre-existing risk awareness (&lt;i&gt;‘Because I have many allergies […]’&lt;/i&gt;, P14, female, late 30s) and occurring symptoms in the child (&lt;i&gt;‘I saw a rash […] and googled it […]’&lt;/i&gt;, P06, female, early 40s) influenced the parents' behaviour. Limited competence in finding valuable information was found to be a barrier to prevention and risk prediction of childhood FA (&lt;i&gt;‘[…] the Internet is big and wide’&lt;/i&gt;, P15, female, mid 30s). Parents' information needs ranged from no interest (&lt;i&gt;","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"943-945"},"PeriodicalIF":6.3,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14569","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epithelial Interleukin-1 Receptor-Like-1 Activation Is Contingent on Interleukin-33 Isoforms and Asthma-Related Receptor Variation 上皮细胞白细胞介素-1 受体样-1 激活取决于白细胞介素-33 同工型和哮喘相关受体变异。
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-20 DOI: 10.1111/cea.14562
Michael A. Portelli, Maria E. Ketelaar, Stewart Bates, Eszter Csomor, Dominick Shaw, Jonas Emsley, Christopher Brightling, Ian Hall, Karen Affleck, Matthew Edwards, Martijn C. Nawijn, Gerard H. Koppelman, Antoon J. Van Oosterhout, Ian Sayers

Introduction

The interleukin-33/interleukin-1 receptor-like-1 (IL-33/IL1RL1) signalling pathway is implicated in asthma pathogenesis, with IL1RL1 nonsynonymous genetic polymorphisms associated with disease risk. We aimed to determine these variants' effect on IL1RL1 signalling induced by different IL33 isoforms thought to be elevated in the asthmatic airway.

Method

In a project funded by GSK plc, which has developed an IL-33 receptor inhibitor for asthma treatment, human embryonic kidney 293 (HEK293) cells expressing secreted embryonic alkaline phosphatase (SEAP) driven by a nuclear factor kappa-beta (NF-κB) promoter, were transiently transfected with IL1RL1, containing one of four extracellular and Toll/interleukin 1 receptor (TIR) domain haplotypes. Cells were stimulated with seven different splice and proteolytic-generated IL-33 isoforms (0.001–50 ng/mL) for 24 h. Supernatant SEAP activity and interleukin-8 (IL-8) levels were determined. Primary human bronchial epithelial cells (HBECs) representing different genotype carriers were stimulated with IL-33112–270 (50 ng/mL) and induced IL-8 mRNA expression measured.

Results

HEK293 cells carrying both asthma extracellular and TIR domain IL1RL1 risk haplotypes presented maximal IL33-driven signalling, with minimal signalling after IL-33 activation in other protective haplotypes. All IL-33 isoforms activated IL1RL1 but with differing magnitudes. Proteolytically cleaved IL3395–270 and IL33106–270 had the greatest effect and the IL33113–270, and Exon 3,4 deletion isoform exhibited the lowest. The effect of extracellular and TIR domain genetic variants on receptor signalling was replicated in primary HBECs. Maximal IL1RL1 signalling was observed in cells carrying both extracellular and TIR signalling domain risk haplotypes.

Conclusions

Overall, our study suggests asthma patients carrying the extracellular and TIR domain risk haplotype and have a lung microenvironment that promotes elevated levels of cleaved IL33, particularly where IL3395–270 and IL33106–270 may be more amenable to IL33/IL1RL1 targeting.

导言:白细胞介素-33/白细胞介素-1受体样-1(IL-33/IL1RL1)信号通路与哮喘发病机制有关,IL1RL1非同义遗传多态性与疾病风险相关。我们旨在确定这些变异对哮喘气道中被认为升高的不同 IL33 异构体所诱导的 IL1RL1 信号传导的影响:在一个由葛兰素史克公司(GSK plc)资助的项目中(该公司已开发出一种用于治疗哮喘的IL-33受体抑制剂),表达由核因子卡巴-β(NF-κB)启动子驱动的分泌型胚胎碱性磷酸酶(SEAP)的人胚胎肾脏293(HEK293)细胞被瞬时转染了含有四种细胞外和Toll/白介素1受体(TIR)结构域单倍型之一的IL1RL1。用七种不同的剪接和蛋白水解产生的 IL-33 异构体(0.001-50 毫微克/毫升)刺激细胞 24 小时,测定上清液 SEAP 活性和白细胞介素-8(IL-8)水平。用 IL-33112-270(50 ng/mL)刺激代表不同基因型携带者的原代人支气管上皮细胞(HBECs),并测定诱导的 IL-8 mRNA 表达:结果:携带哮喘细胞外结构域和TIR结构域IL1RL1风险单倍型的HEK293细胞呈现最大的IL33驱动信号,而其他保护性单倍型细胞在IL-33激活后信号最小。所有 IL-33 异构体都能激活 IL1RL1,但激活程度不同。蛋白水解IL3395-270和IL33106-270的作用最大,而IL33113-270和外显子3、4缺失异构体的作用最小。细胞外和 TIR 结构域基因变体对受体信号的影响在原代 HBECs 中得到了复制。在携带细胞外和TIR信号结构域风险单倍型的细胞中观察到了最大的IL1RL1信号传导:总之,我们的研究表明,携带细胞外和 TIR 信号结构域风险单倍型的哮喘患者的肺部微环境会促进裂解 IL33 水平的升高,尤其是 IL3395-270 和 IL33106-270 可能更适合 IL33/IL1RL1 靶向。
{"title":"Epithelial Interleukin-1 Receptor-Like-1 Activation Is Contingent on Interleukin-33 Isoforms and Asthma-Related Receptor Variation","authors":"Michael A. Portelli,&nbsp;Maria E. Ketelaar,&nbsp;Stewart Bates,&nbsp;Eszter Csomor,&nbsp;Dominick Shaw,&nbsp;Jonas Emsley,&nbsp;Christopher Brightling,&nbsp;Ian Hall,&nbsp;Karen Affleck,&nbsp;Matthew Edwards,&nbsp;Martijn C. Nawijn,&nbsp;Gerard H. Koppelman,&nbsp;Antoon J. Van Oosterhout,&nbsp;Ian Sayers","doi":"10.1111/cea.14562","DOIUrl":"10.1111/cea.14562","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The interleukin-33/interleukin-1 receptor-like-1 (IL-33/IL1RL1) signalling pathway is implicated in asthma pathogenesis, with <i>IL1RL1</i> nonsynonymous genetic polymorphisms associated with disease risk. We aimed to determine these variants' effect on IL1RL1 signalling induced by different IL33 isoforms thought to be elevated in the asthmatic airway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>In a project funded by GSK plc, which has developed an IL-33 receptor inhibitor for asthma treatment, human embryonic kidney 293 (HEK293) cells expressing secreted embryonic alkaline phosphatase (SEAP) driven by a nuclear factor kappa-beta (NF-κB) promoter, were transiently transfected with <i>IL1RL1</i>, containing one of four extracellular and Toll/interleukin 1 receptor (TIR) domain haplotypes. Cells were stimulated with seven different splice and proteolytic-generated IL-33 isoforms (0.001–50 ng/mL) for 24 h. Supernatant SEAP activity and interleukin-8 (IL-8) levels were determined. Primary human bronchial epithelial cells (HBECs) representing different genotype carriers were stimulated with IL-33<sub>112–270</sub> (50 ng/mL) and induced IL-8 mRNA expression measured.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>HEK293 cells carrying both asthma extracellular and TIR domain <i>IL1RL1</i> risk haplotypes presented maximal IL33-driven signalling, with minimal signalling after IL-33 activation in other protective haplotypes. All IL-33 isoforms activated IL1RL1 but with differing magnitudes. Proteolytically cleaved IL33<sub>95–270</sub> and IL33<sub>106–270</sub> had the greatest effect and the IL33<sub>113–270</sub>, and Exon 3,4 deletion isoform exhibited the lowest. The effect of extracellular and TIR domain genetic variants on receptor signalling was replicated in primary HBECs. Maximal IL1RL1 signalling was observed in cells carrying both extracellular and TIR signalling domain risk haplotypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overall, our study suggests asthma patients carrying the extracellular and TIR domain risk haplotype and have a lung microenvironment that promotes elevated levels of cleaved IL33, particularly where IL33<sub>95–270</sub> and IL33<sub>106–270</sub> may be more amenable to IL33/IL1RL1 targeting.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 12","pages":"984-995"},"PeriodicalIF":6.3,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Modelling Links Maternal Hypertensive Disorders to Early Childhood Allergic Disease Burden 全球模型将孕产妇高血压疾病与幼儿过敏性疾病负担联系起来
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-17 DOI: 10.1111/cea.14566
Duan Ni, Ralph Nanan
<p>As common pregnancy-related pathologies, maternal hypertensive disorders (MHD) are widespread globally, exhibiting a spectrum of severity and varying prevalence from pregnancy-induced hypertension to preeclampsia and eclampsia. MHD have been implicated in maternal and foetal immune alterations and are linked to increased allergic diseases in offsprings in several studies, albeit with overall inconclusive results [<span>1, 2</span>]. Here, we harnessed comprehensive global data and systematically assessed the links between MHD and common allergic diseases, atopic dermatitis (AD) and asthma, in offsprings.</p><p>Disease data was obtained from Global Burden of Disease 2019 (GBD2019) database, covering close to 200 countries globally (Figure 1A). Per GBD definition, MHD includes <i>gestational hypertension (onset after 20-week gestation), pre-eclampsia, severe preeclampsia, and eclampsia, but excludes chronic hypertension (onset prior to pregnancy or prior to 20-week gestation) unless superimposed preeclampsia or eclampsia develop</i>. AD refers to <i>relapsing inflammation of the dermal layer of the skin with disruption of the epidermal barrier (dermatitis) associated with elevated serum IgE and some degree of immune dysregulation, which can be localised or widespread</i>. Asthma is defined as <i>a chronic lung disease characterised by reversible airway obstruction due to spasms and secretions in the bronchi usually resulting from an allergic reaction or hypersensitivity and causing difficulty in breathing</i>.</p><p>We focused on the early age group of 1–4-year-old, the peak incidence ages for AD and the first early manifestation of asthma [<span>3</span>]. Ratios of 1–4-year-old AD or asthma cases versus number of pregnancies 2-year prior for each country were calculated. These ratios were used as proxies of percentages of pregnancies with offsprings developing AD (AD%) or asthma (asthma%) at the 2-year-old timepoint. These results were then compared with percentages of MHD-affected pregnancies (MHD%) at 2-year prior timepoint (Figure 1B). They were modelled as close proxies of the links between MHD and offspring allergic diseases. Additionally, socioeconomic status, reflected by GDP, was accounted as a potential confounder [<span>3, 4</span>].</p><p>Figure 1C illustrates the predicted response curves of AD% as a function of MHD%. The most recent available timepoint with complete data coverage, 2018, is shown as representative. Generally, across GDP quantiles (red, 25%; green, 50%; blue, 75%), MHD% were associated with elevated AD%. Likewise, MHD% were associated with increased asthma% (Figure 1D). Interestingly, aforementioned associations seemed to dissipate with age. For example, AD% for 10–14-year-old and 15–19-year-old exhibited less striking correlations with MHD% 12- and 17-year prior, respectively.</p><p>Collectively, we for the first time demonstrated positive associations between MHD% and offspring AD% and asthma% for 1–4-year-old on
作为一种常见的妊娠相关疾病,孕产妇高血压疾病(MHD)在全球范围内广泛存在,其严重程度和患病率各不相同,从妊娠高血压到子痫前期和子痫。在一些研究中,MHD与母体和胎儿的免疫改变有关,并与后代过敏性疾病的增加有关,尽管总体上尚无定论[1,2]。在这里,我们利用了全面的全球数据,系统地评估了MHD与后代常见过敏性疾病、特应性皮炎(AD)和哮喘之间的联系。疾病数据来自2019年全球疾病负担(GBD2019)数据库,涵盖全球近200个国家(图1A)。根据GBD的定义,MHD包括妊娠期高血压(妊娠20周后发病)、子痫前期、重度子痫前期和子痫,但不包括慢性高血压(妊娠前或妊娠20周前发病),除非合并子痫前期或子痫发生。AD是指皮肤真皮层复发性炎症,伴有表皮屏障破坏(皮炎),伴有血清IgE升高和一定程度的免疫失调,可局部或广泛。哮喘被定义为一种慢性肺部疾病,其特征是由支气管痉挛和分泌物引起的可逆性气道阻塞,通常由过敏反应或过敏引起,并引起呼吸困难。我们关注的是1 - 4岁的早期年龄组,这是AD的发病高峰年龄,也是哮喘的第一个早期表现。计算每个国家1 - 4岁AD或哮喘病例与2年前怀孕人数的比率。这些比率被用来代表2岁时发生AD (AD%)或哮喘(asthma%)的后代怀孕的百分比。然后将这些结果与2年前受MHD影响的妊娠百分比(MHD%)进行比较(图1B)。它们被建模为MHD和后代过敏性疾病之间联系的密切代理。此外,GDP反映的社会经济地位也被认为是一个潜在的混杂因素[3,4]。图1C显示了AD%作为MHD%函数的预测响应曲线。具有完整数据覆盖的最新可用时间点(2018年)为代表性。一般来说,在GDP分位数中(红色,25%;绿色,50%;蓝色,75%),MHD%与AD%升高相关。同样,MHD%与哮喘%增加相关(图1D)。有趣的是,上述联系似乎随着年龄的增长而消失。例如,10 - 14岁和15 - 19岁的AD%分别与12年和17年前的MHD%表现出不太显著的相关性。总的来说,我们首次在全球范围内证明了1 - 4岁儿童MHD%与后代AD%和哮喘%之间的正相关。更新后的GBD2021数据也是如此。先前对较小的观察队列的研究主要集中在子痫前期,一种严重的MHD形式。我们的全球分析提供了更全面的概述,涵盖了整个MHD频谱,同时考虑了潜在的外部混杂因素。对于像我们这样的生态学研究,总是存在有关混杂因素的问题。我们试图通过调整GDP等社会经济数据来解释这些问题。值得注意的是,当校正社会人口指数而不是GDP时,我们的发现保持不变,突出了它们的稳健性。MHD和后代过敏之间的相关性似乎随着年龄的增长而消失,这表明营养和污染等其他混杂因素可能会在以后的生活中掩盖MHD的影响。因此,有必要对其他因素进行更全面的研究。本研究的一个主要限制是不同国家和不同时期MHD和过敏性疾病的报告和诊断标准的变化。例如,1 - 4岁年龄组的哮喘不可避免地与一些学龄前喘息病例重叠,这需要更精确的分类,以便将来进行彻底的调查。此外,其他混杂因素,特别是环境因素也可能有所不同。在我们的模型中,通过考虑时间和国家的影响,并根据社会经济学进行调整,这些方面已经得到了部分考虑。此外,全球缺乏MHD实体和AD和哮喘以外的其他过敏性疾病(如食物过敏)的详细细分数据。将来可能会有更全面的数据,可以进行更详细和分层的分析。我们的发现背后的机制尚不清楚。潜在的介质包括与MHD相关的妊娠并发症,如早产和低出生体重,这与更严重的先兆子痫谱系特别相关,但与一般MHD相关性较弱[7,8]。 另一方面,我们之前报道过子痫前期会损害胎儿Treg发育,这对预防特应性反应至关重要,这可能解释了我们的观察结果。研究这些机制是否延伸到其他形式的MHD和其他免疫病理学是必要的。总的来说,与之前报道的一些较小规模的研究中子痫前期和早期儿童过敏之间的联系一致,我们的发现巩固了他们的发现,并提供了一种全新的全球视角。我们的工作还支持健康和疾病的发育起源(DOHAD)概念,并展示了一种新的DOHAD相关研究方法,揭示了母亲对后代非传染性疾病的影响。两位作者都对概念和设计、数据的获取、分析和解释、手稿的起草和重要知识内容的手稿的批判性修改做出了贡献。两位作者都阅读并批准了稿件。作者没有什么可报告的。作者声明无利益冲突。
{"title":"Global Modelling Links Maternal Hypertensive Disorders to Early Childhood Allergic Disease Burden","authors":"Duan Ni,&nbsp;Ralph Nanan","doi":"10.1111/cea.14566","DOIUrl":"10.1111/cea.14566","url":null,"abstract":"&lt;p&gt;As common pregnancy-related pathologies, maternal hypertensive disorders (MHD) are widespread globally, exhibiting a spectrum of severity and varying prevalence from pregnancy-induced hypertension to preeclampsia and eclampsia. MHD have been implicated in maternal and foetal immune alterations and are linked to increased allergic diseases in offsprings in several studies, albeit with overall inconclusive results [&lt;span&gt;1, 2&lt;/span&gt;]. Here, we harnessed comprehensive global data and systematically assessed the links between MHD and common allergic diseases, atopic dermatitis (AD) and asthma, in offsprings.&lt;/p&gt;&lt;p&gt;Disease data was obtained from Global Burden of Disease 2019 (GBD2019) database, covering close to 200 countries globally (Figure 1A). Per GBD definition, MHD includes &lt;i&gt;gestational hypertension (onset after 20-week gestation), pre-eclampsia, severe preeclampsia, and eclampsia, but excludes chronic hypertension (onset prior to pregnancy or prior to 20-week gestation) unless superimposed preeclampsia or eclampsia develop&lt;/i&gt;. AD refers to &lt;i&gt;relapsing inflammation of the dermal layer of the skin with disruption of the epidermal barrier (dermatitis) associated with elevated serum IgE and some degree of immune dysregulation, which can be localised or widespread&lt;/i&gt;. Asthma is defined as &lt;i&gt;a chronic lung disease characterised by reversible airway obstruction due to spasms and secretions in the bronchi usually resulting from an allergic reaction or hypersensitivity and causing difficulty in breathing&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;We focused on the early age group of 1–4-year-old, the peak incidence ages for AD and the first early manifestation of asthma [&lt;span&gt;3&lt;/span&gt;]. Ratios of 1–4-year-old AD or asthma cases versus number of pregnancies 2-year prior for each country were calculated. These ratios were used as proxies of percentages of pregnancies with offsprings developing AD (AD%) or asthma (asthma%) at the 2-year-old timepoint. These results were then compared with percentages of MHD-affected pregnancies (MHD%) at 2-year prior timepoint (Figure 1B). They were modelled as close proxies of the links between MHD and offspring allergic diseases. Additionally, socioeconomic status, reflected by GDP, was accounted as a potential confounder [&lt;span&gt;3, 4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Figure 1C illustrates the predicted response curves of AD% as a function of MHD%. The most recent available timepoint with complete data coverage, 2018, is shown as representative. Generally, across GDP quantiles (red, 25%; green, 50%; blue, 75%), MHD% were associated with elevated AD%. Likewise, MHD% were associated with increased asthma% (Figure 1D). Interestingly, aforementioned associations seemed to dissipate with age. For example, AD% for 10–14-year-old and 15–19-year-old exhibited less striking correlations with MHD% 12- and 17-year prior, respectively.&lt;/p&gt;&lt;p&gt;Collectively, we for the first time demonstrated positive associations between MHD% and offspring AD% and asthma% for 1–4-year-old on ","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 12","pages":"1024-1026"},"PeriodicalIF":6.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14566","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Naturally Occurring Food Chemical Components and Extraintestinal and Gastrointestinal Symptoms in Adults: A Systematic Review 天然食物化学成分与成人肠外症状和胃肠道症状:系统综述。
IF 6.3 2区 医学 Q1 ALLERGY Pub Date : 2024-09-05 DOI: 10.1111/cea.14561
Zoe Cooke, Kathryn Lynam, Caroline Tuck, Gina Louise Trakman

Objective

This systematic review aims to synthesise existing literature to examine the relationship between natural food chemical components and reported symptoms.

Design

A systematic literature review was completed. Databases CINAHL (Ebscohost), Medline (Ovid), Scopus, Informit Health and Google Scholar were searched to identify relevant articles. The population included human studies of adults (≥17 years) and excluded those with IgE-mediate food allergies. Studies examining food chemical components or ‘food chemical elimination diets’ and symptoms were included. Data was synthesised based on clinical conditions and specific food chemical components examined. The risk of bias was assessed using the Academy of Nutrition and Dietetics ‘Quality Criteria Checklist: Primary Research’.

Results

Of the 1659 articles retrieved, 21 met inclusion criteria. This included eight randomised controlled trials, four non-randomised controlled trials, four cohort studies with placebo-controlled challenge, one prospective cohort study, three cross sectional cohort studies, one case–controlled study. Available studies support the role of a low-histamine diet for symptoms in chronic urticaria and low-salicylate diet for reducing sino-nasal symptoms in aspirin exacerbated respiratory disease and chronic rhinosinusitis and/or asthma. While further evidence is needed to verify the role of glutamate in respiratory, pain, asthma and gastrointestinal symptoms.

Conclusions

Food chemical elimination diets may improve condition-specific symptoms across the adult cohorts outlined within this review, with the strongest evidence to support the role of a low-histamine diet for management of symptoms in chronic urticaria and a low-salicylate diet in aspirin exacerbated respiratory disease and/or asthma. Further well-designed trials are needed to elucidate the effect of specific natural food chemical components on symptoms.

Trial Registration

Systematic review number: CRD42022322511.

目的:本系统综述旨在综合现有文献,研究天然食物化学成分与报告症状之间的关系:本系统综述旨在综合现有文献,研究天然食品化学成分与报告症状之间的关系:设计:完成系统性文献综述。检索了 CINAHL (Ebscohost)、Medline (Ovid)、Scopus、Informit Health 和 Google Scholar 等数据库,以确定相关文章。研究对象包括成年人(≥17 岁),但不包括 IgE 媒介型食物过敏者。还包括对食物化学成分或 "消除食物化学成分饮食 "和症状的研究。根据临床情况和所研究的特定食物化学成分对数据进行综合。采用营养与饮食科学院的 "质量标准检查表 "对偏倚风险进行了评估:结果:在检索到的 1659 篇文章中,有 21 篇符合纳入标准。其中包括 8 项随机对照试验、4 项非随机对照试验、4 项安慰剂对照挑战队列研究、1 项前瞻性队列研究、3 项横断面队列研究和 1 项病例对照研究。现有研究支持低组胺饮食对慢性荨麻疹症状的作用,以及低水杨酸饮食对减轻阿司匹林加重的呼吸道疾病和慢性鼻炎和/或哮喘的鼻鼻症状的作用。尽管还需要进一步的证据来验证谷氨酸盐在呼吸道、疼痛、哮喘和胃肠道症状中的作用:本综述概述的成人组群中,食物化学物排除饮食可改善特定症状,其中最有力的证据支持低组胺饮食对慢性荨麻疹症状的控制作用,以及低水杨酸饮食对阿司匹林加重的呼吸道疾病和/或哮喘的作用。要阐明特定天然食物化学成分对症状的影响,还需要进一步设计完善的试验:系统综述编号CRD42022322511。
{"title":"Naturally Occurring Food Chemical Components and Extraintestinal and Gastrointestinal Symptoms in Adults: A Systematic Review","authors":"Zoe Cooke,&nbsp;Kathryn Lynam,&nbsp;Caroline Tuck,&nbsp;Gina Louise Trakman","doi":"10.1111/cea.14561","DOIUrl":"10.1111/cea.14561","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This systematic review aims to synthesise existing literature to examine the relationship between natural food chemical components and reported symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>A systematic literature review was completed. Databases CINAHL (Ebscohost), Medline (Ovid), Scopus, Informit Health and Google Scholar were searched to identify relevant articles. The population included human studies of adults (≥17 years) and excluded those with IgE-mediate food allergies. Studies examining food chemical components or ‘food chemical elimination diets’ and symptoms were included. Data was synthesised based on clinical conditions and specific food chemical components examined. The risk of bias was assessed using the Academy of Nutrition and Dietetics ‘Quality Criteria Checklist: Primary Research’.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 1659 articles retrieved, 21 met inclusion criteria. This included eight randomised controlled trials, four non-randomised controlled trials, four cohort studies with placebo-controlled challenge, one prospective cohort study, three cross sectional cohort studies, one case–controlled study. Available studies support the role of a low-histamine diet for symptoms in chronic urticaria and low-salicylate diet for reducing sino-nasal symptoms in aspirin exacerbated respiratory disease and chronic rhinosinusitis and/or asthma. While further evidence is needed to verify the role of glutamate in respiratory, pain, asthma and gastrointestinal symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Food chemical elimination diets may improve condition-specific symptoms across the adult cohorts outlined within this review, with the strongest evidence to support the role of a low-histamine diet for management of symptoms in chronic urticaria and a low-salicylate diet in aspirin exacerbated respiratory disease and/or asthma. Further well-designed trials are needed to elucidate the effect of specific natural food chemical components on symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Systematic review number: CRD42022322511.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"855-880"},"PeriodicalIF":6.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14561","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Experimental Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1